NOACs effects in the secondary prevention of atrial fibrillation-related ischemic stroke/TIA: a systematic review and meta-analysis
{{output}}
Aims: Rivaroxaban has been approved for the primary prevention of stroke with non-valvular atrial fibrillation caused by one or more risk factors. However, the optimal antithrombotic therapy for secondary prevention of stroke in ... ...
